LUPUS TODAY: RESEARCH INTO ACTION

September 5-6, 2003

Marriott Wardman Park Hotel, Washington, DC

FRIDAY, SEPTEMBER 5, 2003 10:00AM-6:30PM

10:00AM REGISTRATION

11:00AM-11:20AM WELCOMING REMARKS

> Wanda G. Jones, Dr.P.H. Vivian W. Pinn, M.D. Steven J. Hausman, Ph.D.

11:20AM-11:45AM **SESSION I:** LUPUS PRIMER

Joan Merrill, M.D.

An introduction to current issues in lupus care and research.

11:45AM-1:00PM LUNCH BREAK (on your own)

1:00PM-2:30PM **SESSION II:** LUPUS TODAY

This session will present how lupus affects patients of different ages and populations, current clinical diagnostics, and treatments used today in lupus. Speakers will present cutting edge research on the basic mechanisms of the disease and how the new information may translate into new treatments.

The Reproductive Years, the Pregnant Patient and her Infant

Jill P. Buyon, M.D. Jane E. Salmon, M.D.

Children and Adolescent Patients

Christy Sandborg, M.D. Hermine Brunner, M.D.

Race, Ethnicity and the Environment

Patricia A. Fraser, MPH, M.D.

John Reveille, M.D.

2:30PM-3:00PM **COFFEE BREAK: MEET THE SPEAKERS**

3:00PM-4:30PM **SESSION II: LUPUS TODAY** (cont.) The Kidney

Michael P. Madaio, M.D. Gary S. Gilkeson, M.D.

Cardiovascular Lupus

Michelle Petri, M.D.

Neuropsychiatric Lupus

Betty Diamond, M.D. Robin L. Brey, M.D.

4:30PM-5:00PM BREAK: MEET THE SPEAKERS

5:00PM-7:00PM SESSION III: DINNER AND PANEL DISCUSSION

LUPUS TODAY: VIEWPOINTS

Panelists: Patient and Family: Barbara Butler

Participating in Clinical Studies: Debra Lappin

NIH: Susana Serrate-Sztein, M.D.

Advocacy Groups: Alliance for Lupus Research;

American Autoimmune Related

Diseases Association; Arthritis Foundation;

Lupus Clinical Trials Consortium,

Inc.;

Lupus Foundation of America; Lupus Research Institute; Rheuminations, Inc.; S.L.E. Foundation, Inc.

Discussion topics: Challenges Patients Face Today and How They Cope

Advocacy groups, and what is their role

Clinical trials: what they are, and what to expect Issues in patient participation in clinical trials

What are the patients' rights

What is being done to assure protection of clinical study participants

SATURDAY, SEPTEMBER 6, 2003 8:00AM-3:00PM

7:30AM-8:00AM REGISTRATION AND CONTINENTAL BREAKFAST

8:00AM-12:00PM SESSION IV: RESEARCH INTO ACTION

8:00AM-8:20AM Novel Diagnostics

Tim Behrens, M.D.

This session will address emerging technologies and how they are being applied to the development of new diagnostic tools for lupus.

8:20AM-9:45AM INVESTIGATOR-INITIATED CLINICAL TRIALS

Introduction

Susana Serrate-Sztein, M.D.

Speakers will describe current clinical trials in lupus. Each will include a basic overview of the disease mechanisms on which the intervention is thought to work and the outcomes to be measured.

Lupus NephritisMary Anne Dooley, M.D.CVLaura E. Schanberg, M.D.Anti-IL-6Gabor Illei, M.D., MHSB cell therapyJohn Looney, M.D.

9:45 AM-10:15AM BREAK: MEET THE SPEAKERS

10:15AM-11:15AM INVESTIGATOR-INITIATED CLINICAL TRIALS

ToleranceBetty Diamond, M.D.High Dose CytoxanRobert A. Brodsky, M.D.Stem Cell TherapyKenneth Kalunian, M.D.Stem Cell TherapyBarbara Mittleman, M.D.

11:15AM-12:00PM INDUSTRY-INITIATED CLINICAL TRIALS: TBA

12:00PM-12:30PM BREAK AND MEET THE SPEAKERS

12:30PM-3:00PM <u>SESSION V:</u> LUNCH AND PANEL DISCUSSION

RESEARCH INTO THE FUTURE

This session will focus on a panel presentation and discussion of the opportunities for new trials, and discussion of obstacles and possible solutions for expanding current clinical trials in SLE.

Panelists: Clinical trials - FDA point of view Lee S. Simon, M.D.

Clinical trials - the patient view TBA
Research Perspectives from industry Various

Research Perspectives from Intramural NIH Gregory Dennis, M.D.
Research Perspectives from Extramural NIH Susana Serrate- Sztein,

M.D.

Discussion

3:00PM CLOSING REMARKS; ADJOURN